Effect analysis of postoperative immune-enhancing enteral nutrition on immune function in elderly patients with gastric chemotherapy

doi:10.3877/cma.j.issn.1674-0793.2015.06.012

Abstract

Abstract:

Objective

To observe the effect of postoperative immune-enhancing enteral nutrition on elderly gastric cancer patients.

Methods

Eighty patients undergoing chemotherapy after stomach cancer surgery were chosen from January 2014 to February 2015. According to the random number table method, patients were divided into control group and observation group, with 40 patients in each group. The observation group were treated with immune-enhancing enteral nutrition, while the control group with conventional enteral nutrition. Immunoglobulin, T cell subsets, nutrition indicators after chemotherapy, hospital stay defecation, and the first exhaustion time in two groups were compared.

Results

After treatment, compared to the control group, in the observation group IgM, IgG, IgA increased significantly, CD3, CD4, CD8, TF, PA, ALB, Hb were higher (P<0.05), hospital stay time, defecation time and the first exhaustion time were significantly shorter, and these differences were statistically significant (P<0.05).

Conclusion

Postoperative chemotherapy in gastric cancer patients can significantly improve the immune function, and shorten the length of hospital stay, which is worthy of clinical promotion.

Key words: Enteral nutrition, Stomach neoplasms, Immune-enhancing, Immune Function

Rong Zhou, Yidan Lin, Zhiqin Tan. Effect analysis of postoperative immune-enhancing enteral nutrition on immune function in elderly patients with gastric chemotherapy[J]. Chinese Archives of General Surgery(Electronic Edition), 2015, 09(06): 467-470.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2015.06.012

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2015/V09/I06/467

Figures/Tables 4

References 15

1	杨兴无, 林韬, 李河圣, 等. LKB1蛋白在胃癌组织中的表达及其临床意义[J/CD]. 中华普通外科学文献:电子版, 2012, 6(1): 51-56.
2	黄师菊, 周雪玲, 李慧娟, 等. 胃癌患者围手术期营养状况对生活质量的影响调查[J/CD]. 中华普通外科学文献:电子版, 2013, 7(5): 400-403.
3	杨志锋, 江小梅.胃癌患者近远期预后影响因素的COX模型分析[J/CD]. 中华普通外科学文献:电子版, 2014, 8(3): 209-212.
4	Nagano T, Fujita H, Tanaka T, et al. Randomized controlled trial comparing antioxidant-enriched enteral nutrition with immune-enhancing enteral nutrition after esophagectomy for cancer: a pilot study[J]. 2013, 43(11): 1240-1249.
5	冯春在, 苏永辉, 侯冰宗, 等. 乌司他丁对胃癌患者术后炎症反应的影响[J/CD]. 中华普通外科学文献:电子版, 2013, 7(3): 197-200.
6	许威. 腹腔镜胃癌根治术与开腹胃癌根治术对比研究的现状[J]. 医学综述, 2013, 19(6): 1023-1025.
7	杨志锋, 余元龙, 邓庆炎, 等. 胃癌组织中血管内皮生长因子C的表达与淋巴结微转移的关系[J/CD]. 中华普通外科学文献:电子版, 2014, 8(5): 395-398.
8	Pollock GR, Van Way CW 3rd. Immune-enhancing nutrition in surgical critical care[J]. Mo Med, 2012, 109(5): 388-392.
9	隆斌, 杨世斌, 许峰峰, 等. 胃癌合并腹水182例临床病理特征及预后分析[J/CD]. 中华普通外科学文献:电子版, 2012, 6(3): 238-242.
10	殷婷婷. 血清微量元素与胃蛋白酶原联合检测在胃癌早期诊断中的应用进展[J]. 医学综述, 2014, 20(15): 2697-2699.
11	简卫华, 张娈景, 刘龙山, 等. 靶向沉默SPHK1基因诱导人胃癌SGC-7901细胞凋亡[J/CD]. 中华普通外科学文献:电子版, 2012, 6(3): 205-209.
12	Inoue M, Kinoshita K, Sano F, et al. Perioperative nutritional support with immune-enhancing diet for surgical closure of open thoracic window[J]. Kyobu Geka, 2012, 65(7): 559-562.
13	龚龙波, 吕孝鹏, 孟良, 等. 便秘术后胃排空障碍及肠内营养支持治疗的应用[J/CD]. 中华普通外科学文献:电子版, 2013, 7(5): 367-369.
14	许彬东, 黄国忠, 谢金标, 等. 生长激素强化的肠外营养支持对老年食管癌患者术后机体营养及免疫功能的影响[J/CD]. 中华普通外科学文献:电子版, 2013, 7(5): 358-362.
15	Tremaroli V, Karlsson F, Werling M, et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation[J]. Cell Metab, 2015, 22(2): 228-238.

组别	例数	IgM		IgG		IgA
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	0.98±0.36	1.85±0.42	9.97±2.92	13.38±2.09	1.87±0.65	2.39±0.32
对照组	40	0.99±0.41	1.58±0.51	10.58±2.88	12.26±2.21	1.93±0.63	2.17±0.23
t值	?	0.116	2.585	0.350	2.350	0.419	3.531
P值	?	0.908	0.012	0.941	0.021	0.676	0.001

组别	例数	IgM		IgG		IgA
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	0.98±0.36	1.85±0.42	9.97±2.92	13.38±2.09	1.87±0.65	2.39±0.32
对照组	40	0.99±0.41	1.58±0.51	10.58±2.88	12.26±2.21	1.93±0.63	2.17±0.23
t值	?	0.116	2.585	0.350	2.350	0.419	3.531
P值	?	0.908	0.012	0.941	0.021	0.676	0.001

组别	例数	CD3		CD4		CD8
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	58.42±10.59	61.7±6.6	31.21±6.18	35.9±7.3	21.23±5.21	23.7±5.5
对照组	40	56.81±6.58	56.4±7.2	29.92±7.89	31.6±6.4	20.67±5.`13	21.1±5.3
t值	?	0.817	3.432	0.815	2.801	0.484	2.051
P值	?	0.417	0.001	0.417	0.006	0.630	0.044

组别	例数	CD3		CD4		CD8
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	58.42±10.59	61.7±6.6	31.21±6.18	35.9±7.3	21.23±5.21	23.7±5.5
对照组	40	56.81±6.58	56.4±7.2	29.92±7.89	31.6±6.4	20.67±5.`13	21.1±5.3
t值	?	0.817	3.432	0.815	2.801	0.484	2.051
P值	?	0.417	0.001	0.417	0.006	0.630	0.044

组别	例数	TF（mg/L）	PA（mg/L）	ALB（g/L）	Hb（g/L）
观察组	40	147.6±36.4	202.8±33.7	29.3±4.6	105.2±18.9
对照组	40	129.3±37.2	183.7±36.4	25.9±4.8	92.8±21.8
t值	?	2.224	2.435	3.234	2.718
P值	?	0.029	0.017	0.002	0.008

Please choose a citation manager

Content to export